journal article·2023-07-19

Organic Phase-Soluble Nanomagnetically Cationic Phospholipid: Synthesis, Characterization, and In Vitro Transfection Activity

Babak Kaboudin, Hiroshi Aoyama, Akihiro Sugiyama, Yoko Endo-Takahashi, Yoichi Negishi

ACS Applied Materials & Interfaces· Volume 15· Issue 28
Publisher page

Abstract

The presented work describes the synthesis and characterization of a novel magnetic cationic phospholipid (MCP) system with a stable dopamine anchor as well as its transfection activity study. The synthesized architectural system increases the biocompatibility of iron oxide and promises applications of magnetic nanoparticles in living cells. The MCP system is soluble in organic solvents and can be easily adapted to prepare magnetic liposomes. We created complexes with liposomes containing MCP and other functional cationic lipids and pDNA as gene delivery tools, which possessed the ability to enhance the efficiency of transfection, particularly the process of interaction with cells by inducing a magnetic field. The MCP is able to create iron oxide nanoparticles and has the potential for the materials to prepare the system for site-specific gene delivery with the application of an external magnetic field.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Gava Zang, Zanjan 45137-66731, Iran

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan

Funding

Japan Society for the Promotion of Science · Institute for Advanced Studies in Basic Sciences

References (33)

Show source-provided references
1. 10.1021/acs.bioconjchem.0c0036610.1021/acs.bioconjchem.0c00366 ↗
2. 10.1038/nrg376310.1038/nrg3763 ↗
3. 10.1016/j.ymthe.2017.03.01310.1016/j.ymthe.2017.03.013 ↗
4. 10.1089/nat.2018.072110.1089/nat.2018.0721 ↗
5. 10.1186/s40824-019-0156-z10.1186/s40824-019-0156-z ↗
6. 10.3390/pharmaceutics1212121610.3390/pharmaceutics12121216 ↗
7. 10.3390/nano705009410.3390/nano7050094 ↗
8. 10.1021/nn504905q10.1021/nn504905q ↗
9. 10.1021/acsbiomaterials.6b0053610.1021/acsbiomaterials.6b00536 ↗
10. 10.1021/acsanm.9b0250110.1021/acsanm.9b02501 ↗
11. 10.1021/acs.chemmater.9b0355210.1021/acs.chemmater.9b03552 ↗
12. 10.1038/nmat125110.1038/nmat1251 ↗
13. 10.1016/j.biomaterials.2004.10.01210.1016/j.biomaterials.2004.10.012 ↗
14. 10.1021/ja065135510.1021/ja0651355 ↗
15. 10.1073/pnas.84.21.741310.1073/pnas.84.21.7413 ↗
16. 10.1016/S2213-2600(15)00245-310.1016/S2213-2600(15)00245-3 ↗
17. 10.1021/bc900393r10.1021/bc900393r ↗
18. 10.1039/C5OB02512E10.1039/C5OB02512E ↗
19. 10.1021/jm900897a10.1021/jm900897a ↗
20. 10.1039/C7TB01080J10.1039/C7TB01080J ↗
21. 10.1016/j.bbamem.2005.04.00810.1016/j.bbamem.2005.04.008 ↗
22. 10.1021/nl304287a10.1021/nl304287a ↗
23. 10.1194/jlr.M200356-JLR20010.1194/jlr.M200356-JLR200 ↗
24. 10.1021/acs.nanolett.9b0424610.1021/acs.nanolett.9b04246 ↗
25. 10.1002/adma.20150582210.1002/adma.201505822 ↗
26. 10.1002/adma.20160694410.1002/adma.201606944 ↗
27. 10.1021/acs.jmedchem.5b0167910.1021/acs.jmedchem.5b01679 ↗
28. 10.1038/s41563-020-00886-010.1038/s41563-020-00886-0 ↗
29. 10.1126/sciadv.abf439810.1126/sciadv.abf4398 ↗
30. 10.1126/sciadv.aba102810.1126/sciadv.aba1028 ↗
31. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
32. 10.1038/nbt.160210.1038/nbt.1602 ↗
33. 10.1016/j.omtm.2020.07.01510.1016/j.omtm.2020.07.015 ↗